in clinical trials includes darapladib, which yields promising results in the prevention and attenuation of events related to coronary artery disease.[1][2][7][5][6] ## Review Questions - [Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=27140&utm_source=pubmed&utm_campaign=reviews&utm_content=27140) - [Comment on this article.](https://www.statpearls.com/articlelibrary/commentarticle/27140/?utm_source=pubmed&utm_campaign=comments&utm_content=27140) ## References 1. Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011 Oct 12;111(10):6130-85. \[[PMC free article: PMC3196595](/pmc/articles/PMC3196595/)\] \[[PubMed: 21910409](https://pubmed.ncbi.nlm.nih.gov/21910409)\] 2. Magrioti V, Kokotos G. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present). Expert Opin Ther Pat. 2013 Mar;23(3):333-44. \[[PubMed: 23294257](https://pubmed.ncbi.nlm.nih.gov/23294257)\] 3. Glukhova A, Hinkovska-Galcheva V, Kelly R, Abe A, Shayman JA, Tesmer JJ. Structure and function of lysosomal phospholipase A2 and lecithin:cholesterol acyltransferase. Nat Commun. 2015 Mar 02;6:6250. \[[PMC free article: PMC4397983](/pmc/articles/PMC4397983/)\] \[[PubMed: 25727495](https://pubmed.ncbi.nlm.nih.gov/25727495)\] 4. Wolf G. Adipose-specific phospholipase as regulator of adiposity. Nutr Rev. 2009 Sep;67(9):551-4. \[[PubMed: 19703262](https://pubmed.ncbi.nlm.nih.gov/19703262)\] 5. Naini SM, Choukroun GJ, Ryan JR, Hentschel DM, Shah JV, Bonventre JV. Cytosolic phospholipase A2α regulates G1 progression through modulating FOXO1 activity. FASEB J. 2016 Mar;30(3):1155-70. \[[PMC free article: PMC4750418](/pmc/articles/PMC4750418/)\] \[[PubMed: 26644349](https://pubmed.ncbi.nlm.nih.gov/26644349)\] 6. Schneider BE, Behrends J, Hagens K, Harmel N, Shayman JA, Schaible UE. Lysosomal phospholipase A2: a novel player in host immunity to Mycobacterium tuberculosis. Eur J Immunol. 2014 Aug;44(8):2394-404. \[[PubMed: 24825529](https://pubmed.ncbi.nlm.nih.gov/24825529)\] 7. Murakami M, Taketomi Y, Miki Y, Sato H, Hirabayashi T, Yamamoto K. Recent progress in phospholipase A₂ research: from cells to animals to humans. Prog Lipid Res. 2011 Apr;50(2):152-92. \[[PubMed: 21185866](https://pubmed.ncbi.nlm.nih.gov/21185866)\] 8. Amigoni A, Pettenazzo A, Stritoni V, Circelli M. Surfactants in Acute Respiratory Distress Syndrome in Infants and Children: Past, Present and Future. Clin Drug Investig. 2017 Aug;37(8):729-736. \[[PMC free article: PMC5509808](/pmc/articles/PMC5509808/)\] \[[PubMed: 28510235](https://pubmed.ncbi.nlm.nih.gov/28510235)\] 9. Amer MD, Hedlund E, Rochester J, Caplan MS. Platelet-activating factor concentration in the stool of human newborns: effects of enteral feeding and neonatal necrotizing enterocolitis. Biol Neonate. 2004;85(3):159-66. \[[PubMed: 14646336](https://pubmed.ncbi.nlm.nih.gov/14646336)\] **Disclosure:** Jarett Casale declares no relevant financial relationships with ineligible companies. **Disclosure:** Salah Eddine Kacimi declares no relevant financial relationships with ineligible companies. **Disclosure:** Matthew Varacallo declares no relevant financial relationships with ineligible companies.